Exchange: OTC·Updated 10:36 AM EDT
About DVHGF
Devonian Health Group, Inc. is a clinical-stage pharmaceutical company. The firm is engaged in the development of drugs for a range of autoimmune and fibroinflammatory conditions, using novel therapeutic approaches to address unmet medical needs. It offers therapeutic and cosmeceutical products. Its drug candidate, Thykamine product is issued from Devonian’s SUPREX platform, is a product for the prevention and treatment of health conditions related to inflammation and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune disorders. The company was founded by Andre P. Boulet on March 27, 2015 and is headquartered in Montmagny, Canada.